Clinical trials: Gene Mutations
Non-small Cell Lung Cancer
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor…
- Trial name
- NCT03940703
- Testing
- Tepotinib, Osimertinib
- Where
- 179 sites in United States, Belgium and 15 more
- Volunteers
- 140 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
ALK Gene Mutation, Lung Adenocarcinoma
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
This is an open-label, multiple centers, two-arms phase II study to evaluate the safety and efficacy Pembrolizumab,Bevacizumab in combination with Chemotherapy could improve PFS in Alectinib Failed ALK-rearranged Advanced Lung…
- Conditions
- ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy
- Trial name
- BEYOND (NCT05266846)
- Testing
- Pembrolizumab injection
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Hunan Province Tumor Hospital
Metastatic Colorectal Cancer
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer
This is an open, multicenter phase II trial of therapy with a combination of cetuximab, and irinotecan every second week combined with a daily dose of everolimus to patients with metastatic colorectal cancer with Kirsten rat…
- Trial name
- ICE (NCT01387880)
- Testing
- Everolimus
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Herlev Hospital
Lung Cancer
Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer
This single-centre prospective study is aimed at analysing, by means of liquid biopsy with next generation sequencing analysis on circulating tumor DNA, resistance mutations arising during therapy with selective inhibitors in…
- Trial name
- MUT-ONC (NCT06081270)
- Testing
- Liquid biopsy
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Milano Bicocca
Neuroblastoma
Studying Tumor Samples From Young Patients With Neuroblastoma
This research study is looking at tumor samples from young patients with neuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and…
- Trial name
- NCT00907920
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Children's Oncology Group
Paget's Disease of Bone
Genetic Study of Families Affected by Paget's Disease of Bone
Paget's disease of bone is a frequent bone disorder which usually starts after the age of 40 and which is characterized by bone pain and deformities.
- Trial name
- PAGET (NCT00747994)
- Where
- France
- Volunteers
- 83 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Von Hippel-Lindau Disease
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
Background: Von Hippel-Lindau (VHL) disease is a rare gene disease. People with VHL often have a brain tumor called hemangioblastoma. Standard treatment for these tumors is risky surgery.
- Trial name
- NCT02108002
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Transthyretin Gene Mutations, Transthyretin Amyloidosis
Transthyretin Amyloidosis Outcome Survey (THAOS)
THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM.
- Trial name
- THAOS (NCT00628745)
- Testing
- None. Observational Study.
- Where
- 113 sites in United States, Argentina and 23 more
- Volunteers
- 6,718 people
- Sponsor
- Pfizer
Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma
Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis
This is a two-stage, prospective, single-center observational diagnostic accuracy study evaluating noninvasive urine testing for the detection of urothelial carcinoma (UC).
- Conditions
- Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, UTUC, Bladder Cancer (BC)
- Trial name
- NCT07614594
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Henan Provincial People's Hospital
Systemic Mastocytosis
Imatinib in KIT-negative Systemic Mastocytosis
The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Imatinib Mesylate therapy in patients with systemic mastocytosis lacking KIT mutations.
- Trial name
- NCT01297777
- Testing
- Imatinib Mesylate
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Virgen de la Salud
Posterior Column Ataxia With Retinitis Pigmentosa
Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1
The goal of this clinical trial is to evaluate a specific antisense oligonucleotide medication in one patient with posterior column ataxia with retinitis pigmentosa.
- Trial name
- NCT06565572
- Testing
- nL-FLVC-001
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Colorado, Denver
Amyloid Neuropathies, Familial
Early and Systematic Screening in Chronic Neuropathy
TTR-FAP is a rare disabling inherited disorder that predominantly affects the peripheral nervous system and the heart. Due to an important phenotypic and genetic heterogeneity, the diagnosis is often delayed, preventing therefore…
- Trial name
- TTR-FAP (NCT03720275)
- Testing
- Systematic screening of TTR mutations
- Where
- France
- Volunteers
- 130 people
- Sponsor
- University Hospital, Bordeaux
Lazertinib
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
Using gefitinib or Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with active mutations in epithelial cell growth factor receptors (EGFR), 70% response rate (CR+PR) and 90% disease control rate (CR+PR+SD)…
- Trial name
- NCT06156527
- Testing
- Lazertinib, Bevacizumab Injectable Product
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- National Cancer Center, Korea
Gastrointestinal Malignancies
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations.
- Trial name
- NCT05229588
- Testing
- Lurbinectedin 4 MG Injection [Zepzelca]
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- HonorHealth Research Institute
Familial Mediterranean Fever, Heat Intolerance
Heat Intolerance in the Group of FMF Patients
There now causation between Heat Intolerance and FMF that were showed in studies till now. We suggest that the prevalence of Heat Intolerance in the group of the FMF patients will be significantly higher than in the group of…
- Conditions
- Familial Mediterranean Fever, Heat Intolerance, Heat Tolerance Test
- Trial name
- NCT01059279
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Sheba Medical Center
Carcinoma, Non-Small-Cell Lung, Lung Diseases
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
This is a multicohort phase 2 study to evaluate the efficacy of pembrolizumab combined with the investigational drug sitravatinib in the frontline treatment of advanced, non-squamous PD-L1 positive NSCLC.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Metastatic Lung Non-Small Cell Carcinoma
- Trial name
- NCT04925986
- Testing
- Sitravatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sarah Goldberg
Triple Negative Breast Cancer, Locally Advanced Breast Cancer
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
Patients with locally advanced unresectable or metastatic programmed cell death ligand (PD-L1) positive triple negative breast cancer (TNBC) will be treated with radiation to one-four sites of metastasis amenable to radiation…
- Conditions
- Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
- Trial name
- NCT05233696
- Testing
- Nab-paclitaxel, Paclitaxel, Radiation Therapy
- Where
- United States
- Sponsor
- University of Colorado, Denver
Colorectal Carcinoma, Liver Metastases
Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness
In this study, colorectal cancer patients with initially resectable liver-only metastases, as prospectively confirmed by a local multidisciplinary team (MDT) according to predefined criteria, will be tested for RAS and BRAF tumor…
- Trial name
- NCT05881746
- Testing
- anatomical liver resection, nonanatomical liver resection
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Fudan University
Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
This was a multicenter, open-label phase 2 study. This study aimed to evaluate the efficacy and safety of JMT101 combined with Osimertinib in participants with local advanced or metastatic non-small-cell lung cancer harbouring…
- Trial name
- NCT06391944
- Testing
- JMT101 Injection, Osimertinib tablet
- Where
- China
- Volunteers
- 161 people
- Sponsor
- Shanghai JMT-Bio Inc.
Ovarian Cancer, Breast Cancer
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such…
- Trial name
- ROSY-O (NCT04421963)
- Testing
- Olaparib
- Where
- 107 sites in United States, Belgium and 21 more
- Volunteers
- 185 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.